Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Pulmonary drug delivery route is used to inhale medication through the respiratory tract. The medication reaches the blood stream through the alveolar surface of the lungs. Pulmonary route of drug administration is mainly used in the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

The global pulmonary drug delivery systems market is estimated to account for US$ 30,005.80 Mn in terms of value in 2020 and is expected to reach US$ 41,072.7 Mn by the end of 2027.

Global Pulmonary Drug Delivery Systems Market: Drivers

Increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel growth of the global pulmonary drug delivery systems market over the forecast period. For instance, according to the study ‘Chronic Obstructive Pulmonary Disease in Latin America’, published in January 2019 in the journal Annals of Global Health, the prevalence of COPD in Latin American cities ranged between 6.2 and 19.6% in individuals aged 40 years and above. 

Moreover, advantages associated with pulmonary drug delivery route are also expected to aid in growth of the market. These advantages include, ease of administration, requires low amount of drug compared to that in oral dosage, very less or negligible side effect, quick onset of action, drug degradation by liver is avoided, targeted drug delivery, and larger absorption area for lungs.

MDIs held dominant position in the global pulmonary drug delivery systems market in 2019, accounting for 53.9% share in terms of value, followed by DPIs and nebulizers, respectively

Figure 1. Global Pulmonary Drug Delivery Systems Market Share (%), by Value, by Product Type, 2019

Pulmonary Drug Delivery Systems  | Coherent Market Insights

Global Pulmonary Drug Delivery Systems Market: Restraints

Stringent regulatory scenario is expected to hinder growth of the market. Regulatory requirements for pulmonary drug delivery systems are quite challenging as MDIs and DPIs are considered as drug-device combination products, and therefore, are regulated under new provisions by the drug regulatory authorities due to the following factors:

  • Product performance is the combination of individual function of both device and drug formulation
  • Product operating technique may affect the dose administration
  • Product manufacturing and use have significant impact on environment

Moreover, various mechanical, chemical, and immunological barriers along with behavioral barriers of poor adherence and poor inhaler technique also limit growth of the market.

request-sample

Pulmonary Drug Delivery Systems Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 28,700.0 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.6% 2027 Value Projection: US$ 41,072.7 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Product Type: Nebulizers, MDIs, DPIs.
  • By Application: Asthma, COPD, Cystic Fibrosis.
Companies covered:

3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare

Growth Drivers:
  • Product Launches
  • Technological Advancement
Restraints & Challenges:
  • Stringent Regulations
  • Patent Losses

Global Pulmonary Drug Delivery Systems Market: Opportunities 

R&D in dry powder inhalation is expected to offer lucrative growth opportunities for players in the global pulmonary drug delivery systems market. For instance, in June 2020, researchers from University of Szeged, Hungary, reported development of a carrier-based DPI system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with suitable shape and size for pulmonary application.

Moreover, adoption of vibrating mesh nebulizers for emerging therapeutics is expected to ensure adequate aerosol drug delivery, thereby aiding in growth of the market.

The global pulmonary drug delivery systems market was valued at US$ 28,700.0 Mn in 2019 and is forecast to reach a value of US$ 41,072.7 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027.

Figure 2. Global Pulmonary Drug Delivery Systems Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Pulmonary Drug Delivery Systems  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the market are focused on adopting various marketing strategies to enhance their market share. For instance, in December 2019,        Glenmark Pharmaceuticals Ltd. secured National Pharmaceutical Pricing Authority’s (India) nod for separate price for its digital dose inhaler or ‘Digihaler’.

Launch of devices to track usage of MDIs is boosting growth of the market. For instance, in November 2019, Lupin Ltd. launched a device – Adhero – to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.

Global Pulmonary Drug Delivery Systems Market: Competitive Landscape

Major players operating in the global pulmonary drug delivery systems market include, 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.

Global Pulmonary Drug Delivery Systems Market: Key Developments

Major players in the market are focused on approval and launch of new devices to expand their product portfolio. For instance, in April 2019, Glenmark Pharmaceuticals Ltd. launched two new steroid inhalers that include Soprobec (beclometasone), a metered-dose aerosol inhaler, and Stalpex (salmeterol/fluticasone), a breath-actuated inhaler.

Orally inhaled and nasal drug products (OINDPs) are the products which include metered dose (MDIs), dry powder inhalers (DPIs), nasal sprays and nebulizers. According to FDA, respiratory inhalers are classified under Class II medical devices. All inhaled products have to undergo mandatory test for extractables, leachables and microbial contaminants. Specific tests for OINDPs include aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). These tests are regarded as key parameters for assessing performance of the OINDPs. In addition, nasal sprays and MDIs are supplemented by tests to monitor the performance of the actuator and metering valve such as plume geometry and spray pattern.

Restraints of the Global Pulmonary Drug Delivery Systems Market

Major factors hampering the growth of the pulmonary drug delivery systems market during the forecast period constitutes of stringent regulations, and complications in use.

Key features of the study:

  • This report provides in-depth analysis of the global pulmonary drug delivery systems market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global pulmonary drug delivery systems market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Pulmonary Drug Delivery Systems Market, By Product Type:
    • Nebulizers
    • MDIs
    • DPIs
  • Global Pulmonary Drug Delivery Systems Market, By Application:
    • Asthma
    • COPD
    • Cystic Fibrosis
  • Global Pulmonary Drug Delivery Systems Market, By Geography:
    • North America
      • By Product Type
        • Nebulizers
        • MDIs
        • DPIs
      • By Application
        • Asthma
        • COPD
        • Cystic Fibrosis
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Product Type
        • Nebulizers
        • MDIs
        • DPIs
      • By Application
        • Asthma
        • COPD
        • Cystic Fibrosis
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type
        • Nebulizers
        • MDIs
        • DPIs
      • By Application
        • Asthma
        • COPD
        • Cystic Fibrosis
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product Type
        • Nebulizers
        • MDIs
        • DPIs
      • By Application
        • Asthma
        • COPD
        • Cystic Fibrosis
      • By Country
        • Brazil
        • Argentina
        • Mexico
        • Rest of LATAM
    • Middle East:
      • By Product Type
        • Nebulizers
        • MDIs
        • DPIs
      • By Application
        • Asthma
        • COPD
        • Cystic Fibrosis
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type
        • Nebulizers
        • MDIs
        • DPIs
      • By Application
        • Asthma
        • COPD
        • Cystic Fibrosis
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • 3M Health Care*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Allied Healthcare Products, Inc.
    • AstraZeneca plc
    • Boehringer Ingelheim
    • CareFusion Corporation
    • GF Health Products, Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.
    • Philips Healthcare

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Application
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
  4. Global Pulmonary Drug Delivery Systems Market, By Product Type, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Nebulizers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • MDIs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • DPIs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Pulmonary Drug Delivery Systems Market, By Application, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Asthma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • COPD
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Cystic Fibrosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
  6. Global Pulmonary Drug Delivery Systems Market, By Regions, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • 3M Health Care
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Allied Healthcare Products, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • CareFusion Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GF Health Products, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Omron Healthcare, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Other Major Players
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 25 figures on “Pulmonary Drug Delivery Systems Market – Global forecast to 2027.

Frequently Asked Questions

The global pulmonary drug delivery systems market was valued at US$ 28,700.0 Mn in 2019 and is forecast to reach a value of US$ 41,072.7 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027.
Major factor driving the growth of global pulmonary drug delivery systems market during the forecast period include product launches, and technological advancement.
Major factors hampering the growth of the pulmonary drug delivery systems market during the forecast period constitutes of stringent regulations, and complications in use.
MDIs held dominant position in the global pulmonary drug delivery systems market in 2019.
North America Pulmonary Drug Delivery Systems market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner